Meta AnalysisID 7212
改良释放型氢化可的松对比标准糖皮质激素替代治疗对肾上腺皮质功能不全成人患者的临床、代谢和骨骼效应及安全性：系统评价与Meta分析
CRD42023470809
P: Patients with adrenal insufficiency I: Modified-release or dual-release hydrocortisone tablet (MR-HC) C: Standard oral Glucocorticoid (SC) O: Chnages in clinical, metabolic, and bone parameters, adverse events S: Rand
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7212
- Evidence Id
- 15770
- Core Evidence Id
- 15770
- Source Meta Analysis Id
- 7199
- Herb2 Meta Analysis Id
- HBMA007199
- Crd Id
- CRD42023470809
- Title
- Clinical, Metabolic, and Bone Effects and Safety of Modified-Release Hydrocortisone versus Standard Glucocorticoid Replacement Therapy in Adults with Adrenal Insufficiency: A Systematic Review and Meta-Analysis
- Review Question
- P: Patients with adrenal insufficiency I: Modified-release or dual-release hydrocortisone tablet (MR-HC) C: Standard oral Glucocorticoid (SC) O: Chnages in clinical, metabolic, and bone parameters, adverse events S: Randomized or non-randomized active-controlled trial
- Study Type Included
- Randomized or non-randomized trials
- Condition Being Studied
- Adrenal insufficiency
- Participant
- Inclusion criteria: 1) Randomized or non-randomized trials published in a peer-reviewed journal; 2) Subjects aged 18 years or older; 3) Primary or secondary adrenal insufficiency switched from SG to MR-HC replacement; 4) Clinical outcomes (quality of life); 5. Metabolic outcome measures (anthropometric, glucose, and lipid metabolism); 6. Bone outcomes (bone mineral density); 7. Adverse events. Exclusion criteria: (1) trials involving animals or healthy human subjects; (2) retrospective studies; (3) review articles, letters, case reports, and conference proceedings; (4) articles that provided inadequate information of interest or primary data; (5) studies reporting on glucocorticoid usage for nonendocrine conditions, and endocrine conditions other than AI.
- Animal
- Human Disease Modelled
- Intervention
- Patients with AI started or switched to modified-release or dual-release hydrocortisone tablet (MR-HC)
- Comparator Control
- Patients with AI started or continued standard oral glucocorticoid (SC)
- Main Outcome
- Changes in clinical, metabolic, and bone parameters Measures of effect Mean difference (95% confidence interval) or odds ratios
- Outcome Measure
- Additional Outcome
- Adverse events Measures of effect Odds ratios
- Study Method
- Meta-analysis, Systematic review
- Keyword
- MeSH headings have not been applied to this record
- Contact
- A.B.M. Kamrul-Hasan [email protected]
- Organisational Affiliation
- Mymensingh Medical College
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Bangladesh
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-10-09
- Registration Date
- 2023-10-19
- Anticipated Start Date
- 2023-10-20
- Anticipated Completion Date
- 2023-11-30
- Title Cn
- 改良释放型氢化可的松对比标准糖皮质激素替代治疗对肾上腺皮质功能不全成人患者的临床、代谢和骨骼效应及安全性：系统评价与Meta分析
- Title En
- Clinical, Metabolic, and Bone Effects and Safety of Modified-Release Hydrocortisone versus Standard Glucocorticoid Replacement Therapy in Adults with Adrenal Insufficiency: A Systematic Review and Meta-Analysis
- Bilingual Status
- complete